在KEYNOTE-A39中,与铂类化疗(吉西他滨加顺铂或卡铂)相比,Keytruda加Padcev在总生存期(OS)和无进展生存期(PFS)方面表现出统计学上显著且具有临床意义的改善。 在中位随访17.3个月(范围:0.3-37.2个月)时,有30%(n=133/442)的Keytruda与Padcev联合疗法组患者死亡,此数值在铂类化疗组为51%(n=226/444)。接...
在KEYNOTE-A39中,与铂类化疗(吉西他滨加顺铂或卡铂)相比,Keytruda加Padcev在总生存期(OS)和无进展生存期(PFS)方面表现出统计学上显著且具有临床意义的改善。 在中位随访17.3个月(范围:0.3-37.2个月)时,有30%(n=133/442)的Keytruda与Padcev联合疗法组患者死亡,此数值在铂类化疗组为51%(n=226/444)。接...
抗肿瘤药物临床试验常用的终点依据来源可分为三类:基于死亡事件的终点,如OS及OS率;基于肿瘤测量的终点,如采用实体瘤疗效评价标准(response evaluation criteria in solid tumors,RECIST)评估的ORR,或基于RECIST和访视的至进展时间(time to progression,TTP)、PFS和至治疗失败时间(time to treatment failure,TTF)等;基于...
[12]Penson RT, Valencia RV, Cibula D, et al. Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial. ...
[3]Rudin CM, Awad MM, Navarro A, et al. Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study. J Clin Oncol. 2020;38(21):2369-2379. ...
[1] IMFINZI® (durvalumab) significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trial. Retrieved April 5, 2024, from https://www.businesswire.com/news/home/20240405027111/en ...
[3] Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer. Mol Cancer 2023 Jul 06;22(1)[4] Decision of the commissioner. Proposal to withdraw approval for the breast cancer indication for AVASTIN (Bevacizumab). FDA. 2011 [5] Shun Lu, et al. 2022 ESMO IO....
3月7日,国际顶尖期刊《新英格兰医学杂志》发表了一篇名为“Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer ”的研究论文,此论文表明了一项ADC/Keytruda组合疗法III期结果: Padcev联用Keytruda一线治疗la/mUC患者的生存结局明显优于化疗,安全性结果与先前报告的一致,未发现新的安全性问题...
参考文献 Provencio M, Serna R, Nadal E, et al. Progression free survival and overall survival in NADIM II study. Presented at 2022 World Conference on Lung Cancer; August 6-9, 2022; Vienna, Austria; abstract PL03.12....
[4]Peters S, Pujol JL, Dafni U, et al. Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy - results from the randomised phase II ETOP/IFCT 4-12 S...